[go: up one dir, main page]

MA27847A1 - Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle. - Google Patents

Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle.

Info

Publication number
MA27847A1
MA27847A1 MA28634A MA28634A MA27847A1 MA 27847 A1 MA27847 A1 MA 27847A1 MA 28634 A MA28634 A MA 28634A MA 28634 A MA28634 A MA 28634A MA 27847 A1 MA27847 A1 MA 27847A1
Authority
MA
Morocco
Prior art keywords
disorders
treatment
useful
compounds
alkenyl
Prior art date
Application number
MA28634A
Other languages
English (en)
Inventor
Robert K Baker
Jianming Bao
Shouwu Miao
Kathleen M Rupprecht
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA27847A1 publication Critical patent/MA27847A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Des nouveaux composés de formule développée (I) sont des antagonistes et/ou agonistes inverses du récepteur des cannabinoïdes-1 (CB1) et sont utiles dans le traitement, la prévention et la suppression de maladies régulées par le récepteur CB1. Les composés de la présente invention sont utiles comme médicaments agissant centralement des psychose, défaillance de la mémoire, troubles cognitifs, migraine, neuropathie, troubles neuro-inflammatoires y compris la sclérose en plaques et le syndrome de Guillain-Barre et les séquelles inflammatoires de l'encéphalite virale, accidents cérébro-vasculaires, et traumatisme cr??nien, troubles de l'angoisse, stress, épilepsie, maladie de Parkinson, troubles du mouvement, et schizophrénie. Les composés sont aussi utiles pour le traitement des troubles liés à l'usage de substances toxiques, le traitement de l'obésité ou des troubles de l'alimentation, ainsi que le traitement de l'asthme, la constipation, la pseudo-obstruction intestinale chronique, et la cirrhose du foie.
MA28634A 2003-06-11 2005-12-05 Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle. MA27847A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47785003P 2003-06-11 2003-06-11

Publications (1)

Publication Number Publication Date
MA27847A1 true MA27847A1 (fr) 2006-04-03

Family

ID=33551769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28634A MA27847A1 (fr) 2003-06-11 2005-12-05 Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle.

Country Status (20)

Country Link
US (2) US7485732B2 (fr)
EP (1) EP1636181A1 (fr)
JP (3) JP3939744B2 (fr)
KR (1) KR20060019587A (fr)
CN (1) CN1802351A (fr)
AU (1) AU2004252109B2 (fr)
BR (1) BRPI0411131A (fr)
CA (1) CA2527933C (fr)
CO (1) CO5650244A2 (fr)
EC (1) ECSP056207A (fr)
IL (1) IL172417A0 (fr)
IS (1) IS8146A (fr)
MA (1) MA27847A1 (fr)
MX (1) MXPA05013583A (fr)
NO (1) NO20060141L (fr)
NZ (1) NZ543451A (fr)
RU (1) RU2006100298A (fr)
UA (1) UA83230C2 (fr)
WO (1) WO2005000809A1 (fr)
ZA (1) ZA200509019B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077847A2 (fr) 2002-03-12 2003-09-25 Merck & Co., Inc. Amides substitues
ES2294330T3 (es) 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
UA83230C2 (ru) * 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
WO2005044785A1 (fr) 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkylamines utilisees en tant que modulateurs des recepteurs cannabinoides
CA2606188A1 (fr) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combinaison d'un inhibiteur de la dipeptidyl peptidase-iv et d'un antagoniste du recepteur cb1 cannabinoide dans le traitement du diabete et de l'obesite
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
AR058199A1 (es) * 2005-11-28 2008-01-23 Merck & Co Inc Derivados de 3- alquilazetidina sustituidos con heterociclos
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
PE20071092A1 (es) * 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
WO2007100535A2 (fr) 2006-02-22 2007-09-07 Merck & Co., Inc. Dérivés d'oxyntomoduline
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2698157B1 (fr) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2008118141A2 (fr) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Utilisation de composés de modulation des cannabinoïdes en association avec d'autres composés thérapeutiques comme traitement d'appoint
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
EP2170065A4 (fr) 2007-06-20 2011-11-23 Merck Sharp & Dohme Alcanes diphényl-substitués
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2212313A2 (fr) * 2007-10-24 2010-08-04 Merck Sharp & Dohme Corp. Synthèse et formes cristallines d'antagoniste/agoniste inversé de cb-1
EP2095814A1 (fr) * 2008-02-26 2009-09-02 Wolfgang J. Kox Sevrage de la nicotine aidé par médicament
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
AR073412A1 (es) 2008-10-03 2010-11-03 Schering Corp Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP3159331A1 (fr) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tretrazolones utilisées comme inhibiteurs de synthase d'acide gras
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CA2880901A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composes tricycliques antidiabetiques
WO2017034872A1 (fr) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Dérivés d'indazole à utiliser en tant qu'agonistes inverses de cb-1
KR20220080015A (ko) 2016-04-22 2022-06-14 악셀레론 파마 인코포레이티드 Alk7 결합 단백질 및 이들의 용도
AU2019325479B2 (en) * 2018-08-20 2025-07-31 Bessor Pharma, Llc Novel cannabinoids and cannabinoid acids and their derivatives
EP3924058A1 (fr) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
WO2021026047A1 (fr) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
GEAP202416395A (en) 2020-08-18 2024-02-12 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052383A (en) * 1974-10-30 1977-10-04 Schering Corporation N-diphenylalkyl-2-benzyl azacyclic compounds
US4133881A (en) * 1977-04-27 1979-01-09 A. H. Robins Company, Incorporated Azetidinyl acetonitrile and acetamide antiarrhythmia compositions and methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
AU723349B2 (en) 1996-06-07 2000-08-24 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1999004794A1 (fr) 1997-07-25 1999-02-04 Merck & Co., Inc. Amines cycliques modulant l'activite des recepteurs de chimiokines
IL141769A0 (en) * 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
CA2372887A1 (fr) 1999-05-25 2000-11-30 Sepracor Inc. Composes heterocycliques analgesiques et procedes d'utilisation de ces derniers
US6635661B2 (en) * 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
GB0117387D0 (en) 2001-07-17 2001-09-05 Novartis Ag Organic compounds
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
EP1581517B1 (fr) 2002-12-23 2007-02-21 Janssen Pharmaceutica N.V. Derives substitues de 1-piperidine-4-yl-4-azetidine-3-yl-piperazine et leur utilisation en tant qu'antagonistes de la neurokinine
EP1618105A1 (fr) 2003-05-01 2006-01-25 Vernalis Research Limited Derives azetidinecarboxamide et leur utilisation pour le traitement de troubles a mediation du recepteur du cb1
CA2524251A1 (fr) 2003-05-01 2004-11-11 Vernalis Research Limited Derives d'azetidinecarboxamide et leur utilisation dans le traitement de troubles medies par les recepteur cb1
UA83230C2 (ru) 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
EP1718609A1 (fr) 2004-02-17 2006-11-08 Laboratorios Del Dr. Esteve, S.A. Composes d'azetidine substitues, preparation et utilisation comme medicaments
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives

Also Published As

Publication number Publication date
JP2011144196A (ja) 2011-07-28
IS8146A (is) 2005-11-24
CO5650244A2 (es) 2006-06-30
CA2527933A1 (fr) 2005-01-06
US20090069284A1 (en) 2009-03-12
JP2007186518A (ja) 2007-07-26
MXPA05013583A (es) 2006-03-09
CA2527933C (fr) 2009-08-11
US7485732B2 (en) 2009-02-03
UA83230C2 (ru) 2008-06-25
ZA200509019B (en) 2006-11-29
AU2004252109B2 (en) 2010-04-08
US7906503B2 (en) 2011-03-15
ECSP056207A (es) 2006-04-19
NO20060141L (no) 2006-03-13
IL172417A0 (en) 2006-04-10
JP2007500246A (ja) 2007-01-11
CN1802351A (zh) 2006-07-12
RU2006100298A (ru) 2006-05-10
KR20060019587A (ko) 2006-03-03
NZ543451A (en) 2008-08-29
WO2005000809A1 (fr) 2005-01-06
BRPI0411131A (pt) 2006-07-18
AU2004252109A1 (en) 2005-01-06
EP1636181A1 (fr) 2006-03-22
JP3939744B2 (ja) 2007-07-04
US20060293299A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
MA27847A1 (fr) Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle.
MA27185A1 (fr) Amides substitues actifs au niveau du recepteur de cannabinoides-1
EP1496838A4 (fr) Amides substitues
DE60316829D1 (de) Substituierte furoä2,3-büpyridin derivate
EP1492784A4 (fr) 2,3-diphenyl-pyridines substituees
MA30086B1 (fr) Derives de 3-alkylazetidine a substituants heterocycliques.
ATE452890T1 (de) Substituierte naphthyridinonderivate
WO2003086288A3 (fr) Amides bicycliques
WO2003082190A3 (fr) Amides spirocycliques en tant que modulateurs du recepteur cannabinoide
WO2003063781A3 (fr) Imidazoles substitues en tant que modulateurs du recepteur cannabinoide
WO2005027837A3 (fr) Sulfonamides substitues
WO2003007887A3 (fr) Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides
ATE501151T1 (de) Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren
NO20063381L (no) CB1 modulatorforbindelser
NO20074961L (no) Imidazopyridazinforbindelser
ATE449074T1 (de) 2-azabicyclo 3.3.1 nonan-derivate als antagonisten des opioid-rezeptors
TW200508203A (en) 3-azabicyclo 3.2.1 octane derivatives
WO2007064566A3 (fr) Derives d'azetidine 3-alkyl substitues par heterocycle
WO2006041797A3 (fr) Hydrazides acycliques utiles en tant que modulateurs du recepteur cannabinoide
WO2007035823A3 (fr) Antagonistes partiels de mglur5 et leurs méthodes d'utilisation
DE602006013040D1 (de) Substituierte pyradinon-derivate als alpha2-adrenorezeptor-antagonisten
TH66053A (th) เอไมด์ที่ถูกแทนที่
WO2003081256A3 (fr) Diagnostics et therapeutique pour des maladies associees au recepteur 21 orphelin couple a la proteine g humain (gpr21)